Benefits of ADHD Treatment in Detained People

Phase 3 Recruiting 150 enrolled Stéphanie Baggio Netherlands Institute for the Study of Crime · collab School of Health Sciences Fribourg · collab University of Geneva, Switzerland · collab University of Lausanne · collab

RandomizedParallel-groupTriple-blindTreatment

Summary

Attention deficit hyperactivity disorder (ADHD) is characterized by difficulties paying attention, poor impulse control, and hyperactive behaviors. It is associated with several health and social detrimental outcomes and leads to increased risks of criminality and recidivism. However, to date, ADHD treatment has been neglected in prison. This project will test the efficacy of ADHD treatment using a randomized controlled trial.

Timeline

Start: 2024-01-01
Primary completion: 2026-10-30
Completion: 2027-10-30

Publications

Baggio S, Billieux J, Dirkzwager A, Iglesias K, Moschetti K, Perroud N, Schneider M, Vernaz N, Wolff H, Heller P. Protocol of a monocentric, double-blind, randomized, superiority, controlled trial evaluating the effect of in-prison OROS-methylphenidate vs. placebo treatment in detained people with attention-deficit hyperactivity disorder (BATIR). Trials. 2024 Jan 4;25(1):23. doi: 10.1186/s13063-023-07827-7.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Methylphenidate	Small molecule	18 mg	Oral
Subject	Methylphenidate	Small molecule	72 mg	Oral

Benefits of ADHD Treatment in Detained People

Summary

Timeline

Publications

Drugs

Indications